13 completed, 11 recruiting, 9 active not recruiting, 6 unknown. 51 Phase 3, 6 Phase 2.
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-11-06 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN HSK39297, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 370 | 2026-04-07 | 2026-05-28 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN iptacopan - Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 31 | 2025-11-27 | 2026-09-09 |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis Telitacicept - IgA Nephropathy (IgAN), IgAVN | Phase 3 | Not yet recruiting | Guixia Ding | 124 | 2025-08-01 | 2025-07-10 |
| Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. zigakibart - Kidney Diseases, Kidney Diseases, Chronic | Phase 3 | Recruiting | Novartis Pharmaceuticals | 220 | 2025-07-28 | 2026-08-17 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| A Trial of HRS-5965 Capsule in Primary IgA Nephropathy HRS-5965, Placebo - Primary IgA Nephropathy | Phase 3 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 378 | 2025-06-04 | 2025-08-05 |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Biogen | 454 | 2025-05-08 | 2026-10-14 |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria SC0062 strength 10mg, Placebo matched to SC0062 - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 360 | 2025-02-14 | 2025-02-17 |
| Effect of Finerenone in IgA Nephropathy Finerenone, Placebo - IgA Nephropathy | Phase 3 | Unknown | Zhejiang University | 120 | 2024-10-08 | 2024-08-30 |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Povetacicept, Placebo (matched to Povetacicept) - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 605 | 2024-08-30 | 2026-05-15 |
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy Telitacicept 160mg, Corticosteroid, ACE Inhibitor or Angiotensin receptor antagonist - IgA Nephropathy (IgAN) | Phase 3 | Active not recruiting | The Affiliated Hospital of Xuzhou Medical University | 150 | 2024-08-01 | 2025-08-01 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD Prednisolone, Prednisolone plus Cyclophosphamide - Glomerulonephritis, IGA | Phase 3 | Recruiting | Air Force Military Medical University, China | 208 | 2024-02-01 | 2024-05-06 |
Showing 20 of 51. Sign in to see all of them.
Proteinuria (13) · Glomerulonephritis (9) · Renal Insufficiency, Chronic (9) · Kidney Diseases (8) · Urologic Diseases (6) · Autoimmune Diseases (3) · Immune System Diseases (3) · Nephritis (3) · Urogenital Diseases (2) · Acute Kidney Injury (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · IgA Vasculitis (1) · Male Urogenital Diseases (1)
Female Urogenital Diseases (50) · Female Urogenital Diseases and Pregnancy Complications (50) · Male Urogenital Diseases (50) · Urogenital Diseases (49) · Autoimmune Diseases (48) · Immune System Diseases (48) · Nephritis (48) · Urologic Diseases (45) · Kidney Diseases (43) · Glomerulonephritis (42) · Pathological Conditions, Signs and Symptoms (18) · Signs and Symptoms (13) · Urination Disorders (13) · Urological Manifestations (13) · Pathologic Processes (10)
Methylprednisolone (4) · Prednisolone (4) · telitacicept (4) · Atrasentan (3) · Mycophenolic Acid (3) · Prednisone (3) · iptacopan (3) · AMG623 peptibody (2) · Angiotensin-Converting Enzyme Inhibitors (2) · Cyclophosphamide (2) · Irbesartan (2) · ravulizumab (2) · Adenosine Triphosphate (1) · Adrenal Cortex Hormones (1) · Angiotensin Receptor Antagonists (1)
Novartis Pharmaceuticals (8) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Alexion Pharmaceuticals, Inc. (2) · Anthera Pharmaceuticals (2) · Calliditas Therapeutics AB (2) · Chinese University of Hong Kong (2) · Sun Yat-sen University (2) · Vertex Pharmaceuticals Incorporated (2) · A. Manzoni Hospital (1) · Air Force Military Medical University, China (1) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · Assistance Publique - Hôpitaux de Paris (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Biogen (1) · Biohaven Therapeutics Ltd. (1)
China (27) · United States (22) · South Korea (20) · Spain (17) · Taiwan (17) · Australia (16) · Germany (16) · France (15) · Italy (15) · United Kingdom (15) · Argentina (14) · Canada (14) · Czechia (14) · Japan (13) · Belgium (12)
Anping Xu, MD (1) · Byung-Joo Park, MD,PhD,FISPE (1) · Cheuk Chun Szeto, MD (1) · Eric Michael, MD (1) · Hee Gyung Kang, Ph.D (1) · Hong Zhang, MD, PHD (1) · Jicheng Lv, Doctor (1) · Jicheng Lv, M.D. (1) · Jie Wang (1) · Jinli Zhang, MD (1) · Juergen Floege, Prof. Dr. (1)
PMID 38299639, PMID 38864363, PMID 37772889, PMID 26032537, PMID 26630142, PMID 35675911, PMID 40465397, PMID 10093981, PMID 10676716, PMID 11877568, PMID 14694168, PMID 18587715, PMID 23675422, PMID 23782179, PMID 28341274, PMID 28763548, PMID 31907076, PMID 36270561, PMID 36685528, PMID 37015244, PMID 37254256, PMID 37591292, PMID 37914086, PMID 37931634, PMID 38059359, PMID 39331470, PMID 39453772, PMID 39455063, PMID 39460694, PMID 39462308, PMID 39724565, PMID 40482854, PMID 40627446, PMID 41196369, PMID 41211929, PMID 41426046, PMID 41428405, PMID 41442197, PMID 41620980, PMID 41661687, PMID 41910396, PMID 42127391, PMID 42205925, PMID 42242268, PMID 42384439, PMID 42633049, PMID 42713733, PMID 42909451
2016 (1), 2017 (1), 2023 (1), 2025 (1)